Christopher Johnson
Psychiatry · East Saint Louis, ILNPI 1205975448
Payments from drug & device makers
Across 177 payments — averaging $15.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$554
- Johnson & Johnson$547
- Alkermes, Inc.$432
- Teva Pharmaceuticals USA, Inc.$347
- Neurocrine Biosciences, Inc.$246
- AbbVie$154
- plus $492 from 9 others
What the payments were for
- Food & beverage$2,765100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 46 | $554 |
| Johnson & Johnson | 32 | $547 |
| Alkermes, Inc. | 32 | $432 |
| Teva Pharmaceuticals USA, Inc. | 16 | $347 |
| Neurocrine Biosciences, Inc. | 14 | $246 |
| AbbVie(2 entities) | 8 | $154 |
| Vanda Pharmaceuticals Inc. | 8 | $144 |
| Axsome Therapeutics, Inc. | 3 | $76 |
| Almatica Pharma LLC | 3 | $52 |
| Lundbeck LLC | 3 | $45 |
| Tris Pharma Inc | 2 | $44 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $36 |
| Ironshore Pharmaceuticals Inc. | 2 | $33 |
| Bausch Health US, LLC | 1 | $19 |
How this compares
$2,772 in reported general payments places this provider in the 80th percentile of 1,344 psychiatry providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 110 | $272,803 |
| Invega TrinzaPaliperidone Palmitate | 26 | $179,442 |
| IngrezzaValbenazine Tosylate | 14 | $111,677 |
| Abilify MaintenaAripiprazole | 35 | $97,561 |
| NuplazidPimavanserin Tartrate | 13 | $62,814 |
| Aripiprazole | 141 | $22,355 |
| Chlorpromazine Hcl | 43 | $19,627 |
| Lurasidone Hcl | 52 | $18,380 |
| Divalproex Sodium ErDivalproex Sodium | 199 | $10,824 |
| Clozapine OdtClozapine | 26 | $8,347 |
| TrintellixVortioxetine Hydrobromide | 15 | $8,190 |
| Risperidone | 382 | $5,794 |
| Paliperidone ErPaliperidone | 15 | $4,875 |
| Quetiapine Fumarate | 272 | $4,518 |
| Olanzapine | 184 | $3,847 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $547 | $452,245136 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $246 | $111,67714 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $554 | $97,56135 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $36 | $8,19015 claims |
| Almatica Pharma LLCSertraline Hcl | $52 | $3,199474 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,344 psychiatry providers in Illinois.
Other psychiatry in East Saint Louis
- Jeffrey RossNorthbrook$10.8M
- Yuhwen ChowChicago$8.5M
- Mark LermanNorthbrook$4.5M
- Danesh AlamWinfield$2.7M
- John ZajeckaSkokie$2.5M
- Riaz BaberNaperville$2.4M
- Michael GreenbaumLibertyville$2.2M
- Sandeep GaonkarNaperville$1.8M
- Jon GrantChicago$1.4M
- David KempOak Lawn$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.